Furthermore, T2DM not only increases the prevalence of MASLD but also contributes to sarcopenia through impaired insulin signaling, reduced anabolic hormone activity, and chronic inflammation that accelerate muscle loss [10]. This evidence concerns the gene INS and sarcopenia.